WFRF:(Wolf Eric T. T.)
Sökning: WFRF:(Wolf Eric T. T.) > (2020-2022) > Potential risks of ...
- 1 av 12
- Föregående post
- Nästa post
- Till träfflistan
Potential risks of treating bacterial infections with a combination of β-lactam and aminoglycoside antibiotics : A systematic quantification of antibiotic interactions in E. coli blood stream infection isolates
-
- Fatsis-Kavalopoulos, Nikos (författare)
- Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi,Dan Andersson
-
- Roelofs, Lex (författare)
- Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi,Dan Andersson
-
- Andersson, Dan I. (författare)
- Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi
- (creator_code:org_t)
- Elsevier, 2022
- 2022
- Engelska.
- Ingår i: EBioMedicine. - : Elsevier. - 2352-3964. ; 78
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- BackgroundTreatment of Blood Stream Infections (BSIs) with a combination of a β-lactam and an aminoglycoside antibiotic is widely used in intensive care units (ICUs) around the world. However, no studies have systematically examined how these drugs interact and potentially influence the antimicrobial efficacy of the overall treatment.MethodsWe collected 500 E. coli isolates from the Uppsala University hospital that were isolated from blood of patients with suspicion of infection. Of those we tested the efficacy of combinations of 2 common β-lactam antibiotics (Ampicillin and Cefotaxime) combined with 2 common aminoglycosides (Gentamicin and Tobramycin) on 254 isolates. The efficacy of all 4 pairwise combinations in inhibiting bacterial growth was then examined on all susceptible strains. That was done by quantifying the Fractional Inhibitory index (FICi), a robust metric for antibiotic combinatorial behaviour, of all possible treatments on every strain. When non additive interactions were identified, results of the original screen were verified with time kill assays. Finally, combination behaviours were analysed for potential cross correlations.FindingsOut of the 4 antibiotic combinations screened none exhibited synergistic effects on any of the 254 strains. On the contrary all 4 exhibited important antagonistic effects on several isolates. Specifically, the combinations of AMP-GEN and CTX-GEN were antagonistic in 1.97% and 1.18% of strains respectively. Similarly, the combinations of AMP-TOB were antagonistic on 0.78% of all strains. PCA analysis revealed that an important factor on the responses to the combination treatments was the choice of a specific aminoglycoside over another. Subsequent cross correlation analysis revealed that the interaction profiles of combinations including the same aminoglycoside are significantly correlated (Spearman's cross correlation test p<0.001).InterpretationThe findings of this study elucidate potential risks of the common combination treatment for blood stream infections. They also demonstrate, previously unquantified metrics on how antibiotics in combination therapies are not interchangeable with others of the same class. Finally, they reiterate the need for case-by-case testing of antibiotic interactions in a clinical setting.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Nyckelord
- FICi
- Synergy
- Antagonism
- Additivity
- Antibiotics
- Mikrobiologi
- Microbiology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
- 1 av 12
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Fatsis-Kavalopou ...
- Roelofs, Lex
- Andersson, Dan I ...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Infektionsmedici ...
- Artiklar i publikationen
- EBioMedicine
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
